Abstract
Objective: This study aims to investigate the relationship between smokeless tobacco (Maras powder) and cigarette consumption with homocysteine, Paraoxonase-1 (PON-1), Arylesterase (ARE), and Lipoprotein-a (Lp (a)), which are known as risk factors for cardiovascular diseases.
 Material and Methods: The individuals included in the study were divided into three groups as Maras powder users (n = 38), cigarette smokers (n = 38), and healthy volunteers who did not use either tobacco group (n = 38). Serum homocysteine, PON-1, ARE, and Lp (a) levels of all participants were examined.
 Results: When the groups are compared, the highest homocysteine level was in the Maras powder group. While the difference between the control group and the Maras powder group was statistically significant, the difference between the control and smokers groups was statistically insignificant. Although PON values were lower in both the Maras powder and smokers groups than the control group, the difference was significant only in the smoking group. ARE was significantly lower, and Lp (a) was significantly higher in both tobacco smokers groups compared to the control group.
 Conclusion: Serum homocysteine, PON-1, ARE, and Lp (a) level are associated with Maras powder use. Homocysteine may be a useful early marker for cardiovascular disease in those who use Maras powder.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
